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The evolution of myelin 488 million years
ago was a critical step for vertebrate diversi-
fication, co-occurring with the develop-
ment of jaws and primary components of
the brain (Stiefel et al., 2013).Myelin is vital
for biological fitness because it increases the
efficiency and conduction velocity of action
potentials while simultaneously providing
metabolic support for axons (Saab et al.,
2016). The production of new CNS myelin
is indispensable for learning new motor
skills in both juveniles and adults (McKen-
zie et al., 2014; Xiao et al., 2016). Any injury,
disease, or disorder that results in chronic
demyelination can lead to debilitating
conditions, such as multiple sclerosis
(MS), leukodystrophies, Guillain-Barre´
syndrome, and Charcot-Marie-Tooth
disease.
CNS myelin is produced exclusively by
postmitotic oligodendrocytes, which de-
velop from an endogenous pool of cycling
oligodendrocyte progenitor cells (OPCs).
OPCs formanonoverlapping grid through-
out the adult parenchyma, and they are the
mostproliferative cell of theadultCNS,pro-
viding a ready pool of progenitors to pro-
duce new oligodendrocytes and myelin
(Hughes et al., 2013). Indeed, myelin turn-
over from new oligodendrocytes occurs
throughout adulthood, and spontaneous
remyelination occurs after CNS injury;
however, in certain diseases, such as MS,
CNS remyelination becomes impaired,
contributing to progressive declines in
motor function (Franklin and ffrench-
Constant, 2008; Young et al., 2013; Hesp et
al., 2015).
Although focal demyelinating lesions of
CNS white matter are one of the primary
causes of function loss in MS, all current
treatments for the disease target the im-
mune system, including -interferons, na-
talizumab, and teriflunomide (Haghikia et
al., 2013). This focus is understandable be-
cause MS is thought to be an autoimmune
disease and is characterized by overactiva-
tion of the immune system, in particular of
CD4 T cells. Nonetheless, these therapies
only reduce the relapse rate of MS; they do
not prevent progressive functional disabili-
ties or promote CNS repair (Zhang et al.,
2013). Only recently has the promotion of
OPC differentiation and remyelination be-
comeanew focus inMSresearch.A recently
published article inThe Journal of Neurosci-
ence by Mei et al. (2016) builds upon this
trend, identifying -opioid receptor (KOR)
agonism as a powerful strategy for enhanc-
ing oligodendrocyte differentiation and re-
myelination in vivo and providing support
for a novel, clinically relevant therapy for
MS and other demyelinating diseases.
Mei et al. (2014) used a recently devel-
oped micropillar array to simultaneously
screen 250 compounds in a GPCR library
for the potential to promote OPC differen-
tiation and remyelination. The array fea-
tures conical “micropillars” that take
advantage of the inherent myelinating
property of oligodendrocytes, and it allows
researchers to visualize the extent of mem-
brane wrapping by oligodendrocytes with
2-photonmicroscopy and immunolabeling
for myelin basic protein (MBP, a marker of
mature oligodendrocytes) and PDGFR (a
marker of undifferentiated OPCs). By as-
sessing the extent of MBPmyelin “rings”
wrapping the micropillars in each well of a
plate, molecules can quickly be screened for
their potential to alter OPC/oligodendro-
cyte phenotype.
Using this technique, Mei et al. (2016)
found that the selective KOR agonist ()-
U50488 was among the most effective at
promoting OPC proliferation, differentia-
tion, and wrapping. The authors further
demonstrated thatOPCs express KORs and
that KOR-null OPCs failed to enhance re-
myelination following application of ()-
U50488 in culture, confirming that KOR
activation in OPCs is critical for promoting
remyelination. In vivo, KOR deficiency in
OPCs delayed myelination during CNS
development, although myelination even-
tually “caught up” to wild-type levels in
adulthood. In a lysolecithinmodel of demy-
elination targeting the corpus callosum,
()-U50488 promoted remyelination only
in mice possessing KORs on oligodendro-
cytes. Finally, ()-U50488 also stimulated
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maturation of human induced pluripotent
stem cell-derived oligodendrocytes, provid-
ing evidence that the drug has similar effects
on human andmouse cells. Together, these
findings suggest that KORs are potentially
powerful targets to enhance myelination in
the CNS.
Other studies havehinted that opioid re-
ceptor signaling is important fornormaloli-
godendrocyte function in the developing
and injured nervous system. Oligodendro-
cytes express KORs and-opioid receptors,
and they produce varying levels of proen-
kephalin and prodynorphin peptides (li-
gands for all opioid receptors) during cell
maturation (Knapp et al., 2001). Oligoden-
drocytes from jimpy mice, which display
deficits in normal myelination due to a
point mutation in the proteolipid protein
(PLP) gene, have a 90% reduction in
KOR expression compared with wild-type
mice (Knappet al., 2009).Additionally, spe-
cific KOR antagonism in vitro increases
oligodendrocyte death and exacerbates glu-
tamate-induced toxicity of mature oligo-
dendrocytes (Knapp et al., 2001). Together,
these earlier studies provided indirect evi-
dence for a role of KOR signaling in oligo-
dendrocyte function, although none
showed the direct connection between acti-
vation of this receptor andmyelination.
However, Mei et al. (2016) were not the
first to make the connection between KOR
agonism and enhanced oligodendrocyte
myelination, nor the first to specifically
study the effects of ()-U50488 on oligo-
dendrocyte function. Du et al. (2016) dem-
onstrated the effectiveness of KOR agonism
with ()-U50488 in the treatment of exper-
imental autoimmune encephalomyelitis, a
mousemodel ofMS.Most importantly, Du
et al. (2016) showed that KOR-mediated at-
tenuation of disease severity was not due to
the actions of KORs on immune cells, but
rather through promotion of oligodendro-
cyte differentiation and remyelination.
Moreover, while ()-U50488 reduced
disease severity in wild-type mice, this phe-
nomenon was not apparent in KOR-defi-
cient mice. The present work by Mei et al.
(2016) complements these findings and,
by using oligodendrocyte-specific KOR
knock-out mice (in contrast to the glob-
al-KOR knock-out mice used by Du et
al., 2016), provides the additional in-
sight that KOR signaling directly affects
oligodendrocytes.
One significant question left unan-
swered by both theMei et al. (2016) andDu
et al. (2016) papers is the potential signaling
pathways throughwhichKORagonistsme-
diate their effects on oligodendrocyte lin-
eage cells. Although no previous research
specifically addresses this question, signal-
ing pathways involved in both myelination
and KOR activation are likely candidates.
KOR signaling results in the activation of
specifickinase cascades, includingGPCRki-
nases, the MAPK family (ERK1/2, p38, and
JNK), as well as the JAK2/STAT3 and IRF2
cascades (Bruchas and Chavkin, 2010; Fin-
ley et al., 2011; Fang et al., 2013). ERK1/2
signaling is the most plausible pathway
through which KOR agonism might influ-
ence oligodendrocyte myelination, but the
STAT3 pathway could also be amediator of
these effects if activated in oligodendrocyte
lineage cells by ()-U50488. We provide
evidence suggesting the involvement of
these pathways below and in Figure 1.
It is well established that signaling
through ERK1/2 is a critical regulator of
oligodendrocytedevelopment andmyelina-
tion. This pathway is required for themain-
tenanceofmyelinandaxonal integrity in the
adult CNS, and ERK1/2 activation in OPCs
improves remyelination (Fyffe-Maricich et
al., 2013; Ishii et al., 2014). Furthermore, a
recent study showed that sustained ERK1/2
activation in preexisting oligodendrocytes
of adult mice was sufficient to increase my-
elin thickness and enhance axon con-
duction velocity (Jeffries et al., 2016). Im-
portantly, ERK1/2 signaling is necessary for
the transcription of key proteins involved in
myelination, including MOG, MBP, and
PLP, suggesting that KOR activation by
molecules, such as ()-U50488, may en-
hance myelination through the down-
streamactions of ERK1/2 (Ishii et al., 2014).
Indeed, ()-U50488 has been shown to ac-
tivate this signaling cascade in cardiomyo-
cytes (Kim et al., 2011).
An alternative explanation for the remy-
elinating effects of KOR agonism is the acti-
vation of JAK2/STAT3 signaling. Following
CNS injury, OPCs increase expression of
pSTAT3 in regions of enhanced oligoden-
drogenesis, and deletion of STAT3 in
OPCs reduces oligodendrocyte differentia-
tion during development and after injury
(Tripathi and McTigue, 2008; Hesp et al.,
2015; Hackett et al., 2016; Steelman et al.,
2016). Thus, if KOR agonism specifically
triggers STAT3 phosphorylation in oli-
godendrocyte lineage cells, this could
be one avenue through which KORs
exert their promyelinating effects, either
independently or in syngerism with
ERK1/2 signaling.
Understanding downstream KOR acti-
vationpathways is crucial for developing se-
lective or partial agonists that can promote
remyelinationwithout KOR-related side ef-
fects, such as dysphoria or hallucinations, as
these are the result of different signaling
Figure 1. Potential signaling pathways throughwhich KOR agonism could enhance remyelination. KOR binding by agonists, such as ()-U50488, leads to downstream ERK1/2 activation, CREB
phosphorylation, and myelin-related gene (MOG/PLP/MBP) expression. Alternatively, KOR activation could lead to JAK2/STAT3 signaling and pSTAT3-mediated gene transcription.
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cascades downstreamof opioid receptor ac-
tivation (Bruchas and Chavkin, 2010).
SalvinorinA, a naturally occurringKORag-
onist, which is also readilymodifiable, holds
promise as a potential starting point for
activating specific downstream signaling
cascades. For example, a modified version
of Salvinorin A, MOM-SAL-B, has been
shown to cause only “early phase” ERK1/2
activation following KOR binding (McLen-
nan et al., 2008). This knowledge could be
leveraged to engineer partial KOR agoni-
sts with specific remyelination-promoting
properties.
In conclusion, the work of Mei et al.
(2016) and others opens a new door for
researchondemyelinatingdiseases, particu-
larly for MS, which lacks targeted remyeli-
nation therapies. Although there are several
drawbacks to the heavy use of opioid recep-
tor agonists, future research into the mech-
anism of KOR agonism in oligodendrocyte
lineage cells may provide alternative strate-
gies for the development of more clinically
appealing pharmacotherapies.
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